The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 1 (1), 36-43
- https://doi.org/10.1053/jcgh.2003.50006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?Gut, 1998
- Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitisInflammatory Bowel Diseases, 1997
- What predicts quality of life in Crohn's and ulcerative colitis patients?:Gastroenterology, 1995
- Sulfasalazine RevisitedAnnals of Internal Medicine, 1993
- Einfluß der Nahrungsaufnahme auf die Magenentleerung magensaftresistenter Tabletten und Kapseln*Deutsche Medizinische Wochenschrift (1946), 1992
- Microscopic activity in ulcerative colitis: what does it mean?Gut, 1991
- A Double-Blind, Placebo Controlled, Multicentre Study of the Efficacy And Safety of 5-Aminosalicylic Acid Tablets in the Treatment of Ulcerative ColitisCanadian Journal of Gastroenterology, 1990
- Pharmacokinetics of a 5‐aminosalicylic acid enteric‐coated tablet and suppository dosage formAlimentary Pharmacology & Therapeutics, 1989
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987